Azelaic Acid Gel 15% in the management of papulopustular rosacea: A status report on available efficacy data and clinical application

Cutis

Volumn 88, Issue 2, 2011, Pages 67-72

  Del Rosso, James Q ^a,b,c   Bhatia, Neal ^d  

^a VALLEY HOSPITAL MEDICAL CENTER   (United States)

^b TOURO UNIVERSITY NEVADA   (United States)

^c Las Vegas Skin & Cancer Clinics Ltd   (United States)

^d Laser Skin Care Center Dermatology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZELAIC ACID; DERMATOLOGICAL AGENT; DICARBOXYLIC ACID; DOXYCYCLINE;

ARTICLE; DRUG COMBINATION; GEL; HOSPITALIZATION; HUMAN; INTRADERMAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PATHOLOGY; ROSACEA;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; DERMATOLOGIC AGENTS; DICARBOXYLIC ACIDS; DOXYCYCLINE; DRUG THERAPY, COMBINATION; GELS; HUMANS; ROSACEA; SEVERITY OF ILLNESS INDEX;

EID: 80053298320     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Crawford GH, Pelle MT, James WD. Rosacea I: etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-341.
2. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: a report of the national rosacea society expert committee on classification and staging of rosacea. J Am Acad Dermatol. 2002;46:584-587.
3. Quarterman MJ, Johnson DW, Abele DC, et al. Ocular rosacea: signs, symptoms, and tear studies before and after treatment with doxycycline. Arch Dermatol. 1997;133:49-54.
4. Pelle MT, Crawford GH, James WD. Rosacea II: therapy. J Am Acad Dermatol. 2004;51:499-512.
5. Del Rosso JQ, Baldwin H, Webster G. American acne & rosacea society rosacea medical management guidelines. J Drugs Dermatol. 2008;7:531-533.
6. The Drug Efficacy Study of the National Research Council's Division of Medical Sciences, 1966-1969. The National Academies Web site. http://www7.nationalacademies.org/archives/drugefficacy.html. Accessed April 30, 2011.
7. Finacea Gel [package insert]. Morristown, NJ: Intendis, Inc; 2010.
8. Gollnick H, Layton A. Azelaic acid 15% gel in the treatment of rosacea. Exper Opin Pharmacother. 2008;9:2699-2706.
9. Yamasaki K, Gallo RL. The molecular pathology of rosacea [published online ahead of print May 29, 2009]. J Dermatol Sci. 2009;55:77-81.
10. Bamford JT. Rosacea: current thoughts on origin. Semin Cutan Med Surg. 2001;20:199-206.
11. Wilkin JK. Rosacea. pathophysiology and treatment. Arch Dermatol. 1994;130:359-362.
12. Del Rosso JQ. Update on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis. 2006;78:97-100.
13. Dirschka T, Tronnier H, Fölster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol. 2004;150:1136-1141.
14. Oztas MO, Balk M, Ogüs E, et al. The role of free oxygen radicals in the aetiopathogenesis of rosacea. Clin Exp Dermatol. 2003;28:188-192.
15. Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea [published online ahead of print August 5, 2007]. Nat Med. 2007;13:975-980.
16. Yamasaki K, Kanada K, Macleod DT, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes [published online ahead of print November 25, 2010]. J Invest Dermatol. 2011;131:688-697.
17. Fleischer AB Jr. The evolution of azelaic acid. Cutis. 2006;77(suppl 2):4-6.
18. Yamasaki K, Gallo RL. Azelaic acid gel alters kallikrein 5 and cathelicidin expression in epidermal keratinocytes: critical elements in the pathogenesis of rosacea. Poster presented at: 68th Annual Meeting of the American Academy of Dermatology; Miami; FL; March 5-9, 2010.
19. Azelex [package insert]. Irvine, CA: Allergan, Inc; 2004.
20. Thiboutot DM, Fleischer AB Jr, Del Rosso JQ, et al. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol. 2008;7:541-546.
21. Draelos ZD. The rationale for advancing the formulation of azelaic acid vehicles. Cutis. 2006;77(suppl 2):7-11.
22. Draelos ZD. Effects of azelaic acid 15% gel on skin barrier in rosacea. Cosmet Dermatol. 2008;21:259-261.
23. Elewski B, Thiboutot D. A clinical overview of azelaic acid. Cutis. 2006;77(suppl 2):12-16.
24. Del Rosso JQ. Medical treatment of rosacea with emphasis on topical therapies. Expert Opin Pharmacother. 2004;5:5-13.
25. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results of two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48:836-845.
26. Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139:1444-1450.
27. Wolf JE Jr, Kerrouche N, Arsonnaud S. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis. 2006;77(suppl 4):3-11.
28. Del Rosso JQ, Bruce S, Jarratt M, et al. Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea. J Drugs Dermatol. 2010;9:607-613.
29. Fleischer A, Suephy C. The face and mind evaluation study: an examination of the efficacy of rosacea treatment using physician ratings of patient s' self-reported quality of life. J Drugs Dermatol. 2005;4:585-590.
30. Thiboutot DM, Fleischer AB, Del Rosso JQ, et al. A multicenter study of azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. J Drugs Dermatol. 2009;8:639-648.
31. Subramanyan K. Role of mild cleansing in the management of patient skin. Dermatol Ther. 2004;17 (suppl 1):26-34.
32. Del Rosso JQ. The use of moisturizers as an integral component of topical therapy for rosacea: clinical results based on the assessment of skin characteristics study. Cutis. 2009;84:72-76.
33. Del Rosso JQ, Baum EW. Comprehensive medical management of rosacea: an interim study report and literature review. J Clin Aesthet Dermatol. 2008;1:20-25.
34. Del Rosso JQ, Lehman PA, Raney SG. Impact of order of application of moisturizers on percutaneous absorption kinetics: evaluation of sequential application of moisturizer lotions and azelaic acid gel 15% using a human skin model. Cutis. 2009;83:119-124.